Skip to main content

Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS

Publication ,  Conference
Morgans, AK; Sweeney, C; Wallis, CJD; Halabi, S; Armstrong, AJ; Adorjan, P; Ghadessi, M; Verholen, F; Grimm, M-O
Published in: JOURNAL OF CLINICAL ONCOLOGY
2024

Duke Scholars

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2024

Volume

42

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Morgans, A. K., Sweeney, C., Wallis, C. J. D., Halabi, S., Armstrong, A. J., Adorjan, P., … Grimm, M.-O. (2024). Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 42).
Morgans, Alicia K., Christopher Sweeney, Christopher J. D. Wallis, Susan Halabi, Andrew J. Armstrong, Patrick Adorjan, Mercedeh Ghadessi, Frank Verholen, and Marc-Oliver Grimm. “Association between prostate-specific antigen (PSA) level <0.2 ng/mL and risk of radiological progression in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC): Follow-up analysis of ARAMIS.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 42, 2024.

Published In

JOURNAL OF CLINICAL ONCOLOGY

EISSN

1527-7755

ISSN

0732-183X

Publication Date

2024

Volume

42

Issue

16

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences